Online inquiry

IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7329MR)

This product GTTS-WQ7329MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets FGFR2 gene. The antibody can be applied in Gastric Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000141.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2263
UniProt ID P21802
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ7329MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7532MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GC-182
GTTS-WQ2531MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 477
GTTS-WQ10090MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA L19TNF
GTTS-WQ11279MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI4893
GTTS-WQ13981MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ12418MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NI-0401
GTTS-WQ12315MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MT203
GTTS-WQ2834MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG-403
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW